AstraZeneca Issues Statement on Competitor to Nexium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Issues Statement on Competitor to Nexium



AstraZeneca issued a statement regarding the launch of esomeprazole strontium in the United States by Seoul, South Korea-based Hanmi Pharmaceutical and its US marketing partner Amneal Pharmaceuticals.
 
 Amneal Pharmaceuticals reported that the first shipping of esomeprazole strontium was made to three major US pharmaceutical wholesalers on Dec. 18, 2013. Esomeprazole strontium contains the same active moiety (esomeprazole) in a different salt form as found in AstraZeneca's branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is used to treat adult patients for the short term treatment of gastroesophageal reflux disease (GERD). Hanmi Pharmaceutical received FDA approval for esomeprazole strontium delayed-release capsules for oral use in August 2013.  AstraZeneca's Nexium had 2012 sales of $3.9 billion. 

In a press statement, AstraZeneca said that it "is aware of reports that an 505(b)(2) NDA esomeprazole strontium product has been launched in the US by Hanmi Pharmaceutical and affiliates (Hanmi) and its US marketing partner Amneal Pharmaceuticals (Amneal). 

AstraZeneca said that on Sept. 30, 2013, the US Court of Appeals for the Federal Circuit  (CAFC) lifted a temporary injunction against Hanmi’s US launch of its 505(b)(2) NDA esomeprazole strontium product (previously granted on Sept. 13,  2013). AstraZeneca’s appeal of the lower court’s December 2012 claim construction remains pending. After oral argument on Nov. 18, 2013, a decision is expected from the CAFC in early 2014. 

"Depending on the outcome of the appeal, Hanmi's sales are at risk of owing AstraZeneca patent-infringement damages," said AstraZeneca in its statement. "AstraZeneca’s appeal concerns both patents-at-issue in the patent-infringement litigation against Hanmi (US Patent Nos. 5,714,504 and 5,877,192).  AstraZeneca understands that Hanmi’s 505(b)(2) NDA esomeprazole strontium product is not AB-rated and is not automatically substitutable for Nexium."

AstraZeneca said that the developments have no impact on AstraZeneca’s full-year 2013 financial guidance.

Source:  AstraZeneca and Hanmi Pharmaceutical

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here